The board of directors of Kintor Pharmaceutical Limited announced that Dr. Qun LU and Dr. Xiang NI, who are respectively the existing chief technology officer (CTO) and chief medical officer (CMO) of the Company, have been appointed as executive Directors with effect from 14 April 2023. Dr. Lu, aged 57, joined the Group in May 2021 and is currently the CTO of the Group, primarily responsible for chemistry, manufacturing and control (CMC) including drug analysis, formulation development and the production. Dr. Lu has over 20 years of experience in biopharmaceutical industry with proven track record of successfully leading the CMC development of pharmaceutical dosage forms from discovery through commercialisation at various pharmaceutical corporations including Pfizer, Merck and Celgene Corp./Bristol Myers Squibb (the BMS).

Prior to joining the Group, Dr. Lu was an executive director at Celgene Corp./BMS in New Jersey from 2013 to 2019 and from 2019 to 2021 respectively, where she focused on defining and delivering integrated CMC development strategies and outcomes for innovative medicines. She also served as a member of the board of directors of International Consortium for Innovation and Quality in Pharmaceutical Development until 2019. Dr. Lu received her bachelor's degree in Chemistry from Peking University in 1987 and completed her Ph.D. in Physical Chemistry at Arizona State University in 1995.

Dr. Lu carried out post-doctoral studies in Pharmaceutics at the University of Wisconsin ­ Madison from 1996 to 1997. Dr. Ni, aged 54, joined the Group in March 2023 and is currently the CMO of the Group, primarily responsible for the coordination, management and supervision of the medical work of the Group. Dr. Ni has dedicated to the international biopharmaceutical field for more than 20 years, with extensive experience and expertise in the clinical development of new drugs, pharmacovigilance and clinical quality.

Prior to joining the Group, Dr. Ni worked in pharmaceutical companies in the United States and China, like AstraZeneca and several innovative biopharma and biotechnology companies like Akesobio and Aquater. Dr. Ni has facilitated the approval of several global new drug applications (NDAs) and new drug clinical trials (INDs). He also has extensive experience working with global regulatory agencies.

Dr. Ni received his bachelor's degree in Medicine from Southeast University School of Medicine in China in 1992 and his Ph.D. degree from School of Medicine, Temple University in the United States in 2000. Each of Dr. Lu and Dr. Ni has entered into a service contract with the Company for an initial term of three years commencing on 14 April 2023, subject to retirement by rotation and re-election at the general meeting of the Company pursuant to the articles of association of the Company. Ms. Yan LU tendered her resignation as the executive Director and the joint company secretary of the Company with effect from 13 April 2023 to pursue her personal endeavours.

Following the resignation of Ms. Lu, Mr. Wai Chiu WONG, the remaining joint company secretary of the Company, will act as the sole company secretary of the Company.